Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of Thrombosis and Haemostasis : JTH|December 19, 2017
Staphylococcus aureus, master manipulator of the human hemostatic systemL Liesenborghs, P Verhamme, T Vanassche
Acta Clinica Belgica|April 15, 2014
Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 geneC Vandenbriele, K Peerlinck, T de Ravel, et al.
The British Journal of Oral & Maxillofacial Surgery|November 1, 2019
Tranexamic acid to reduce bleeding after dental extraction in patients treated with non-vitamin K oral anticoagulants: design and rationale of the EXTRACT-NOAC trialA Ockerman, M Vanhaverbeke, I Miclotte, et al.
Journal of Thrombosis and Haemostasis : JTH|November 2, 2011
Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulenceT Vanassche, J Verhaegen, W E Peetermans, et al.
Journal of Thrombosis and Haemostasis : JTH|May 1, 2012
Antidote strategies to reverse anticoagulation with TB-402, a long-acting partial inhibitor of factor VIIIM Tangelder, C Long, J Emmerechts, et al.
International Journal of Laboratory Hematology|March 25, 2018
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assaysM Jacquemin, J Toelen, L Feyen, et al.
BMC Cardiovascular Disorders|December 1, 2020
Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF studyM Unverdorben, C von Heymann, A Santamaria, et al.
Thrombosis Research|July 23, 2011
Partial versus complete factor VIII inhibition in a mouse model of venous thrombosisJ Emmerechts, T Vanassche, S Loyen, et al.
Journal of Thrombosis and Haemostasis : JTH|December 20, 2014
Real-world variability in dabigatran levels in patients with atrial fibrillationN C Chan, M Coppens, J Hirsh, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2015
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disordersM Jacquemin, J Toelen, J Schoeters, et al.
Pageof 2